摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

紫堇明 | 485-51-8

中文名称
紫堇明
中文别名
——
英文名称
(3R,1'S)-6,7-(methylenedioxy)-3-(1',2',3',4'-tetrahydro-6',7'-dimethoxy-2'-methylisoquinolin-1'-yl)isobenzofuran-1(3H)-one <(+)-corlumine>
英文别名
(6R)-6-[(1S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolin-1-yl]furo[3,4-e]-[1,3]benzodioxol-8(6H)-one;(6R)-6-[(1S)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinolin-1-yl]furo[3,4-e]-1,3-benzodioxol-8(6H)-one;(+)-corlumine;corlumine;(R)-6-((S)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)-6H-furo[3',4':3,4]benzo[1,2-d][1,3]dioxol-8-one;(+)-Corlumin;(6R)-6-[(1S)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]-6H-furo[3,4-g][1,3]benzodioxol-8-one
紫堇明化学式
CAS
485-51-8
化学式
C21H21NO6
mdl
——
分子量
383.401
InChiKey
SZDGAZFTAUFFQH-RBUKOAKNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    28
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    66.5
  • 氢给体数:
    0
  • 氢受体数:
    7

SDS

SDS:2f62e6d730c95d3ada94da651716d97d
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    5-甲酰基苯并[1,3]二恶茂-4-甲酸乙酯盐酸氢氧化钾叔丁基锂氢气 、 sodium cyanoborohydride 、 三乙胺 、 magnesium bromide 、 作用下, 以 甲醇 为溶剂, 反应 2.75h, 生成 紫堇明
    参考文献:
    名称:
    在苯丙氨酸衍生的前体的1位上通过非对映选择性烷基化进行EPC合成四氢异喹啉。生物碱(+)-Corlumine的合成†
    摘要:
    衍生自(R)-或(S)-苯丙氨酸,(S)-多巴和(S)的1,2,3,4-四氢-N-新戊酰基-异喹啉-3-羧酸1d,2d和3d)-α-甲基多巴,分别用双重(去质子化叔在THF丁基)锂和在1-位(产品烷基化5 - 10)。形成的主要非对映异构体是与羧酸根相反的一侧(相对位置ul -1,3)发生亲电攻击的结果。甚至对苯甲醛(7,8)的添加也是高度立体选择性的(一个如果在亲电子试剂之前添加了MgBr 2醚化物,则仅形成四种非对映异构体中的一部分(300-MHz 1 H-NMR分析)。所获得的某些氨基酸衍生物的是由阳极氧化在脱羧的MeOH(11,12,17)和NaBH 3 CN还原,并转化为已知的1-甲基和1- benzyltetrahydroisoquinolines(15,16)> ee> 95%ee以及ee≥80%ee的邻苯二甲酰异喹啉生物碱(+)-哥伦碱。将此处描述的合成方法与合成对映体纯的
    DOI:
    10.1002/hlca.19870700729
点击查看最新优质反应信息

文献信息

  • 1-Magnesiotetrahydroisoquinolyloxazolines as Chiral Nucleophiles in Stereoselective Additions to Aldehydes:  Auxiliary Optimization, Asymmetric Synthesis of (+)-Corlumine, (+)-Bicuculline, (+)-Egenine, and (+)-Corytensine, and Preliminary <sup>13</sup>C NMR Studies of 1-Lithio- and 1-Magnesiotetrahydroisoquinolyloxazolines
    作者:Robert E. Gawley、Pingsheng Zhang
    DOI:10.1021/jo961164u
    日期:1996.11.15
    Transmetalation of 1-lithiotetrahydroisoquinolyloxazolines with magnesium halides affords Grignard reagents that add to aldehydes with up to 80% selectivity for one of the four possible diastereomeric products. An oxazoline chiral auxiliary derived from camphor provides an optimal blend of diastereoselectivity and isomer separability. Synthetic applications of the optimal auxiliary, patterned after a literature approach in the racemic series, comprise an improved (formal) synthesis of bicuculline, egenine, and corytensine, as well as an efficient synthesis of corlumine. Preliminary NMR studies show that both 1-lithio- and 1-magnesiotetrahydroisoquinolyloxazolines are dynamic mixtures in THF solution at low temperatures. The barrier to pyramidal inversion of the secondary Grignard reagent is in the 9.8-10.1 kcal/mol range, while an upper limit of about 8.2 kcal/mol can be assigned to the barrier to the organolithium inversion.
  • 217. The synthesis and resolution of (±)-corlumine
    作者:Wilson M. Whaley、Morton Meadow
    DOI:10.1039/jr9530001067
    日期:——
  • Method of preventing polymer scale formation
    申请人:Shin-Etsu Chemical Co., Ltd.
    公开号:EP0355575B1
    公开(公告)日:1994-11-02
  • METHODS OF PRODUCING STABILIZED SOLID DOSAGE PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS
    申请人:Mallinckrodt LLC
    公开号:EP2654727A1
    公开(公告)日:2013-10-30
  • Sustained-Release Opiate and Opiate Derivative Compositions
    申请人:Schaefer Carl J.
    公开号:US20110077222A1
    公开(公告)日:2011-03-31
    The present invention provides sustained-release opiate compositions. In particular, the present invention provides sustained-release opiate compositions that include an opiate attached to a blood albumin binder. The present invention also relates to methods of administering an opiate with a sustained release pharmacokinetic profile.
查看更多

同类化合物

阿托喹啉 那可汀 那可丁N-氧化物 诺司卡品 盐酸盐 水合物 细果角茴香碱 紫堇明 盐酸那可丁一水合物 盐酸诺格考平 盐酸白毛莨碱 曲托喹啉 山缘草定碱 咖喏定 北美黄连碱 [S-(R*,R*)]-6,7-二甲氧基-3-(5,6,7,8-四氢-4-羟基-6-甲基-1,3-二氧杂环戊并[4,5-g]异喹啉-5-基)苯酞 [6S,(+)]-6-[(1S)-1,2,3,4-四氢-6,7-二甲氧基-2-甲基异喹啉-1-基]呋喃并[3,4-e]-1,3-苯并二氧戊环-8(6H)-酮 7-氨基-4,5,6-三乙氧基-3-(6,7,8-三甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基)-3H-2-苯并呋喃-1-酮 7-O-去甲基alpha-那可丁 6,7-二甲氧基-3-[(5R)-4-甲氧基-6-甲基-7,8-二氢-5H-[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-3H-2-苯并呋喃-1-酮 3-异喹啉-1-基-3H-2-苯并呋喃-1-酮 (3S)-6,7-二甲氧基-3-[(5S)-6-甲基-5,6,7,8-四氢[1,3]二氧杂环戊并[4,5-g]异喹啉-5-基]-2-苯并呋喃-1(3H)-酮 (3S)-3-[(1R)-6,7-二羟基-8-甲氧基-2-甲基-3,4-二氢-1H-异喹啉-1-基]-6,7-二甲氧基-3H-2-苯并呋喃-1-酮 (-)-荷苞牡丹碱甲溴化物 (-)-荷苞牡丹碱 (-)-荷包牡丹碱甲溴化物 (-)-荷包牡丹碱甲氯化物 (-)-紫堇明 (+)-荷苞牡丹碱甲氯化物 (+)-荷包牡丹碱 hydrastidine isohydrastidine 5,9-bis-(4,5-dimethoxy-3-oxo-phthalan-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline (S,R)-9-bromo noscapine (S)-3-{(R)-9-[(2-chloro-acetylamino)-methyl]-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}-6,7-dimethoxy-phthalide (S)-6,7-dimethoxy-3-{(R)-4-methoxy-6-methyl-9-[(2-morpholino-acetylamino)-methyl]-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}-phthalide (R)-5-((S)-4,5-dimethoxy-3-oxo-phthalan-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinoline-9-carboxylic acid methyl ester 4-(((S)-1-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-5-methoxy-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)butane-1-sulfonic acid ethyl 4-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)benzoate N-(3-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)phenyl)acetamide (S)-3-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-7-hydroxy-6-methoxyisobenzofuran-1(3H)-one ethyl 2-chloro-5-((5R)-5-((1S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-9-yl)benzoate 3-(((S)-1-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-5-methoxy-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)propane-1-sulfonic acid 4-(((S)-5-methoxy-1-((R)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3-oxo-1,3-dihydroisobenzofuran-4-yl)oxy)butane-1-sulfonic acid (3S)-6,7-dimethoxy-3-((5R)-4-methoxy-6-methyl-9-(4-vinylphenyl)-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3H)-one (R)-5-((S)-4,5-dimethoxy-3-oxo-1,3-dihydroisobenzofuran-1-yl)-4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline-9-carbaldehyde N-desmethyl-N-carbethoxynarcotine (S)-3-((R)-9-bromo-4-methoxy-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-6,7-dimethoxyisobenzofuran-1(3H)-one 9-Fluoro-Noscapine 9-Nitro-Noscapine 7-benzyloxy-6-methoxy-3-(4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one 7-benzyloxy-6-methoxy-3-(4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one